Studies measuring serum OPG in PAD patients have shown conflicting results [9–13], On the other hand, the role of OPG as a risk factor for MACE has been more firmly established; however, the extent of this risk has not been consistent among all populations [14–16]. This evidence concerns the gene TNFRSF11B and peripheral arterial disease.